1. Introduction {#s0005}
===============

The interest of researchers in the discovery of selective MAO-A or MAO-B inhibitors is steadily increasing. This interest stems from the therapeutic potential of these inhibitors in neurodegenerative diseases management ([@b0025]). Selective MAO-A inhibitors have employed as effective antidepressants while several MAO-B inhibitors are clinically used in Alzheimer\'s and Parkinson\'s diseases therapy ([@b0045]). The mitochondrial flavoprotein monoamine oxidases (MAOs), which are expressed widely in both neuronal and non-neuronal tissues, are responsible for the oxidative deamination of endogenous as well as exogenous amines. Their two isoforms have different tissue distributions, substrate preference, and inhibitor specificity ([@b0140]). Non-selective and irreversible MAO inhibition is accompanied by a hypertensive crisis risk after ingestion of dietary tyramine, while selective MAO-B or MAO-A inhibitors are free from this potential threat ([@b0040]). Therefore, much effort has been devoted to finding new natural or synthetic selective MAO inhibitors. Prolonged therapy with the clinically used irreversible MAO-B inhibitors has demonstrated undesirable effects that evoking the urgent need for the discovery of reversible alternatives ([@b0045], [@b0100]). [@b0100] developed a new reversible MAO-B inhibitor that efficiently lowering increased GABA levels in Alzheimer's patients and consequently avoiding shortcomings of long-term treatment with current irreversible ones.

Various medicinal properties have been reported from several *Zanthoxylum* species (Rutaceae), including cytotoxic, hepatoprotective, antipyretic, diuretic, antioxidant, and tooth care ([@b0085], [@b0115], [@b0120]). *Z. flavum* Vahl, a rich source of coumarins, alkaloids, and lignans, is an evergreen tree found in Cuba, Jamaica, Bahamas, Hispaniola, Bermuda, Lower Florida Keys, and Puerto Rico. This plant has shown to possess antioxidant, cytotoxic, and mild antimalarial activities ([@b0115], [@b0120]).

Sesamin, a major lignan in *Z. flavum*, and its structurally-related derivatives have been reported to possess multifarious pharmacological activities encompassing anti-inflammatory, anti-carcinogenic, hepatic fatty acid oxidation enhancing, immune-modulatory, antihypertensive, and neuroprotective activities ([@b0105]).

The present study demonstrates, for the first time, selective reversible inhibition of MAO-B enzymatic activity by sesamin. MAO-B activity and oxidative stress are major factors for the occurrence of many neurodegenerative conditions ([@b0080]). Therefore, antioxidant and neuroprotective properties of sesamin along with its MAO-B inhibitory activity will enhance its potential efficacy. This conclusion should be confirmed through further in vivo and clinical studies.

2. Materials and methods {#s0010}
========================

2.1. General experimental procedures {#s0015}
------------------------------------

The ^1^H, ^13^C, and 2D NMR spectra were recorded on a Varian Mercury 400 MHz spectrometer, Bruker Avance DRX spectrometer at 600 MHz (^1^H) and 150 MHz (^13^C) using TMS as an internal standard. The HR-ESI-MS were done using a Bruker Bioapex-FTMS with electrospray ionization. Adsorbents for column Chromatography including Diaion HP-20, Silica gel 60 F254 (0.2 mm, Merck), MN-polyamide-SC-6, and Sephadex™ LH-20. Human recombinant MAO-A and -B were obtained from BD Biosciences. Clorgyline, *R*-(-)-deprenyl hydrochloride, Kynuramine dihydrobromide, phenelzine sulfate, 4-hydroxyquinoline, K~2~HPO~4~ buffer, and DMSO were purchased from Sigma.

2.2. Plant material {#s0020}
-------------------

Stems of *Z. flavum* were collected and identified in August 2003 from Montgomery Botanical Centre, Old culture Road region in Florida by Dr. Charles L. Burnadt and a voucher specimen (518 Audubon, Oxford, MS-38655) has been deposited at his herbarium.

2.3. Extraction and isolation {#s0025}
-----------------------------

Air-dried powdered stems (1.3 kg) were macerated at room temperature with 70% MeOH repeatedly till exhaustion. A dry residue (121.6 g) was obtained after the concentration of the combined extracts under reduced pressure. A water suspension of the crude extract was prepared and partitioning was performed using hexane, chloroform, and ethyl acetate to give three main fractions (F1-F3), respectively. Column chromatography CC (silica gel, 800 g, 3.5 × 150 cm) was used for the fractionation of F2 (22.98 g) eluted with a gradient of hexane-EtOAc of increasing polarities (95:5 to 90:10 to 85:15 to 80:20) to afford 8 sub-fractions (Fr. 1 to Fr. 8). Fr. 1 (316 mg) was fractionated by CC (silica gel, 12 g, 1 × 20 cm) using a gradient of hexane-EtOAc (95:5 to 80:20) to furnish compound **1** (10 mg). Fr. 2 (1 g) was subjected to CC (silica gel, 40 g, 2 × 60 cm) using hexane-EtOAc (85:15) then (70:30) to provide compound **2** (195 mg). Fr. 3 (2 g) was purified by CC (silica gel, 80 g, 1 × 100 cm) using hexane-EtOAc (7:3) to elute compound **3** (615 mg). Fr. 4 (750 mg) was separated using CC (silica gel, 30 g, 1 × 60 cm) eluted with hexane-EtOAc (7:3) affording compound **4** (86 mg). Fr. 6 (350 mg) was subjected to CC (silica gel, 12 g, 1 × 20 cm) eluted with hexane-EtOAc (4:6) to yield compound **5** (16.5 mg). Purification of Fr. 7 (460 mg) by CC (Sephadex™ LH-20, 50 g, 1 × 100 cm) using MeOH yielding compound 6 (7.9 mg). Diaion-HP20 was used for fractionation of the ethyl acetate fraction F3 (11.3 g) starting the elution with distilled H~2~O then MeOH. The methanol soluble fraction (10 g) was initially fractionated via CC (silica gel, 400 g, 5 × 100 cm) using a gradient of DCM-MeOH (98:2 to 7:3) to provide 236 fractions which grouped according to TLC profile into 8 subfractions (E1 to E8). E1 (268.4 mg) was loaded onto (silica gel, 15 g, 1 × 30 cm) using hexane-EtOAc (95:5) to give 10 subfractions from which subfraction 3 (37 mg) was further purified using CC (Sephadex™ LH-20, 30 g, 1 × 80 cm) to give compound **7** (11.8 mg). E2 (600 mg) was separated by CC (silica gel, 25 g, 1 × 30 cm) proceeding with DCM-MeOH (98:2) as an elution system to afford compound **8** (6 mg). Fractionation of E4 (420 mg) by CC (Sephadex™ LH-20, 50 g, 1 × 100 cm) using DCM-MeOH (1:1) affording compound **9** (92 mg) together with other promising subfractions which upon further purification over silica gel using EtOAc-DCM-MeOH (30:30:5.5) yield compound **10** (4.8 mg). Compound **11** (156.8 mg) was isolated via CC (silica gel, 50 g, 1.5 × 30 cm) from E5 (1.2 g) using DCM-MeOH system (80:20 to 75: 25). E6 (2.6 g) was fractionated by MN-polyamide SC-6 (250 g) starting the elution with 100% H~2~O then a gradient of H~2~O-MeOH till 100% MeOH to obtain 8 subfractions which upon further purification via Sephadex™ LH-20 afford compounds **12** (122.7 mg) and **13** (9.6 mg). Compound **14** (77.2 mg) was obtained from E7 (490 mg) by CC (Sephadex™ LH-20, 50 g, 1 × 100 cm) using MeOH.

2.4. Antiprotozoal assay {#s0030}
------------------------

Compounds **1**--**5, 7**--**9**, and **11**--**14** were evaluated for their antiprotozoal activities against *Trypanosoma brucei brucei*. The Alamar Blue assay was used on cell cultures of *Trypanosoma brucei* trypomastigotes ([@b0070]). Three concentrations of the compounds ranging from 10 − 0.25 µg/mL were evaluated. The dose-response curves with the aid of XLfit software were used for computing IC~50~ and IC~90~ values which compared to DFMO as a reference.

2.5. Antimicrobial assay {#s0035}
------------------------

Compounds **1**--**5, 7**--**9**, and **11**--**14** were evaluated for antimicrobial activity against *Escherichia coli* ATCC 35218, *Pseudomonas aeruginosa* ATCC 27853, *Mycobacterium intracellulare* ATCC 23068, *Staphylococcus aureus* ATCC 29213, methicillin-resistant *S. aureus* ATCC 33591, *Candida albicans* ATCC 90028, *C. glabrata* ATCC 90030, *C. krusei* ATCC 6258, *Aspergillus fumigatus* ATCC 204305, and *Cryptococcus neoformans* ATCC 90113. The compounds were tested at 20, 10, 5.0, ... 0.02 µg/mL. Ciprofloxacin was a positive control for bacteria and amphotericin B was a positive control for fungi ([@b0015]).

2.6. Monoamine oxidases (MAO-A/-B) inhibition assay {#s0040}
---------------------------------------------------

The kynuramine oxidative deamination assay was utilized to evaluate the monoamine oxidases inhibitory effects of compounds **1**--**4**, **7**, **9** and **12**--**14** at concentrations of 0.001--100 μM for MAO-A and 0.01--100 μM for MAO-B ([@b0030]). The assay is based on tracking and monitoring the MAO catalyzed conversion of kynuramine to 4-hydroxy quinolone fluorometrically. The conditions of the assay were optimized following the previously published procedure ([@b0065]). The oxidized fluorescent product of kynuramine (4-hydroxyquinoline) was assessed at λ~em~ 380 nm and λ~ex~ 320 nm following the published procedure using the SoftMax Pro program ([@b0095]). The standard inhibitors phenelzine, clorgyline, and deprenyl were used at a concentration range of 0.001 μM to 100 μM with the aid of XL-Fit© software.

2.7. MAO-B kinetics inhibition mechanism with sesamin {#s0045}
-----------------------------------------------------

The determination of the MAO-B inhibition constant (K~i~) by sesamin was carried out through enzymatic assays at different kynuramine concentrations ranging from 1.90 to 500 μM and confined sesamin concentrations. Two concentrations of the inhibitor, one lower and another one higher than its IC~50~ value along with a blank set (in absence of the inhibitor) were assayed to establish K~m~ and V~max~ values of sesamin. The findings were carefully examined for the inhibition category either competitive, uncompetitive, or mixed type ([@b0030], [@b0090]). The results were plotted as double reciprocal Lineweaver-Burk plots and the kinetic parameters K~m~, V~max~, and K~i~ (inhibition/binding affinity) were estimated via SigmaPlot 13.0 and the Enzyme-Kinetics module applying the Michaelis-Menten equation.

2.8. Investigation of sesamin\'s binding behavior with MAO-B {#s0050}
------------------------------------------------------------

The sesamin\'s binding behavior with human MAO-B recombinant enzyme was studied through enzyme-inhibitor complex dissociation by equilibrium dialysis ([@b0035]). Recombinant human MAO-B (50 μg/mL protein) incubated with sesamin (15.0 μM) in an enzyme incubation mixture of 1 mL buffered at pH 7.4 using 100 mM potassium phosphate. Following a 20 min incubation of the reaction mixture at 37 °C, the reaction was terminated by chilling on ice. Overnight dialysis of the formed complex mixture was carried out against potassium phosphate buffer at 4 °C for approximately 14--16 h (replacing the buffer three times). The difference between the catalytic activities of the human MAO-B prior to and following the dialysis process was analyzed. A parallel identical procedure was run for the enzyme control (in absence of the inhibitor) along with the standard inhibitors deprenyl (a selective irreversible MAO-B inhibitor) and phenelzine (a non-selective irreversible inhibitor).

3. Results and discussion {#s0055}
=========================

3.1. Identification of phytochemicals {#s0060}
-------------------------------------

The identification of the isolates was based on their spectroscopic analyses interpretation (MS, 1D, and 2D NMR), compared with the corresponding published data in the literature. The isolated compounds were identified as lupeol (**1**) ([@b0055]), isoimperatorin (**2**) ([@b0115]), sesamin (**3**) ([@b0115]), bergapten (**4**) ([@b0115]), oxypeceudanin hydrate (**5**) ([@b0125]), cubebin (**6**) ([@b0075]), imperatorin (**7**) ([@b0125]), pabulenol (**8**) ([@b0125]), 4-hydroxy-2-methoxyphenyl-6-*O*-syringyl-*β*-ᴅ-glucopyranoside (**9**) ([@b0010]), 5, 6, 3ʹ-trihydroxy-3, 7, 4′-trimethoxyflavone-6-*O*-*β*-ᴅ-glucopyranoside (**10**) ([@b0020]), marmesinin (**11**) ([@b0060]), isorutarin (**12**) ([@b0130]), oxypeucedanin hydrate 3″-*O*-*β*-ᴅ-glucopyranoside (**13**) ([@b0110]), and 5, 4′-dihydroxy-3′-methoxyflavanone-7- (6″-*O*-*α*-ʟ-rhamnopyranosyl)-*β*-ᴅ-glucopyranoside (**14**) ([@b0050]). This study reveals the presence of compounds **5, 6, 8**--**14** in *Z. flavum* for the first time. Coumarins, lignans, and flavonoids are of common occurrence in the genus *Zanthoxylum* and the chemotaxonomic significance of their accumulation within the genus is undeniable. Therefore, the isolated compounds from the plant under study greatly support its chemotaxonomy.

3.2. Determination of MAO-A and -B inhibitory effects {#s0065}
-----------------------------------------------------

This study investigated the in vitro inhibitory effects of sesamin and other isolated compounds on monoamine oxidases (MAOs) catalytic activities ([Table 1](#t0005){ref-type="table"}). Sesamin exhibited maximal selective potency of MAO-B inhibition. Also, compound **2** showed selective MAO-A inhibition activity. Considering the relevant neuroprotective and antioxidant effects of sesamin through attenuation of oxidative stress, boosting the potential therapeutic value of sesamin in oxidative stress associated conditions is expected ([@b0005]).Table 1Inhibition of recombinant human MAO-A and -B by some isolated compounds.CompoundsMAO-A\
IC~50~ (µM)[\*](#tblfn1){ref-type="table-fn"}MAO-B\
IC~50~ (µM)[\*](#tblfn1){ref-type="table-fn"}**1** (lupeol, C~30~H~50~O)nana**2** (isoimperatorin, C~16~H~14~O~4~)**6.98 ± 0.29**na**3** (sesamin, C~20~H~18~O~6~)na**1.45 ± 0.054** (bergapten, C~12~H~8~O~4~)4.43 ± 0.158.85 ± 1.17**7** (imperatorin, C~16~H~14~O~4~)30.0 ± 1.1824.84 ± 2.41**9** (4-hydroxy-2-methoxyphenyl-6-*O*-syringyl-*β*-ᴅ-glucopyranoside, C~22~H~26~O~12~)na85.69 ± 7.77**11** (marmesinin, C~20~H~24~O~9~)nana**12** (isorutarin, C~20~H~24~O~10~)33.20 ± 1.2375.52 ± 4.29**13** (oxypeucedanin hydrate 3″-*O*-*β*-ᴅ-glucopyranoside, C~22~H~26~O~11~)nana**14** (5, 4′-dihydroxy-3′-methoxyflavanone-7- (6″-*O*-*α*-ʟ-rhamnopyranosyl)-*β*-ᴅ-glucopyranoside, C~28~H~34~O~15~)nanaPhenelzine0.221 ± 0.0090.131 ± 0.023Clorgyline0.0075 ± 0.0002--Deprenyl--0.049 ± 0.003[^1]

3.3. Evaluation of MAO-B inhibition kinetic mechanism by sesamin {#s0070}
----------------------------------------------------------------

Analysis of the obtained data involving K~i~, K~m~, and V~max~ values of sesamin represented in [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"} indicated that sesamin inhibited the catalytic function of MAO-B through a mixed manner which allowed binding of sesamin in the active catalytic site or an allosteric site on the enzyme, whether or not kynuramine has already been bound, with different affinities for these two binding sites.Table 2Inhibition/binding affinity constants (K~i~) values for inhibition of recombinant human MAO-B by sesamin, phenelzine, and deprenyl.CompoundsMonoamine oxidase-BK~i~ (µM)[\*](#tblfn2){ref-type="table-fn"}Type of InhibitionSesamin0.4730 ± 0.0760Mixed/ReversiblePhenelzine (ref.)0.0616 ± 0.0062Mixed/IrreversibleDeprenyl (ref.)0.0128 ± 0.0020Mixed/Irreversible[^2]Fig. 1Kinetic characteristics of recombinant human MAO-B inhibition with \[A\] phenelzine, \[B\] deprenyl and \[C\] sesamin. \[V = nmoles/min/mg protein and S = substrate kynuramine concentration (μM)\].

3.4. Study of sesamin\'s binding behavior with MAO-B {#s0075}
----------------------------------------------------

The equilibrium dialysis assay is based on incubating the recombinant enzyme protein with high inhibitor concentrations followed by comprehensive dialysis of the produced complex to provide important information concerning the nature of the sesamin binding with the enzyme based on the reconstituted proportion of the protein catalytic activity. Almost complete inactivation of the enzyme was achieved upon incubation however over 90% of functional recovery of the enzyme was recorded from the enzyme-sesamin incubation mixture next to the overnight dialysis. The blank reaction which was done on the recombinant human MAO-B protein incubated without the inhibitor lost about \>5% of the enzymatic activity during overnight dialysis. Analogous treatment of the enzyme with deprenyl and phenelzine also showed irreversible inhibition/binding with the human MAO-B protein ([@b0035], [@b0090]). These observations clearly indicated the dialyzable nature of the enzyme-sesamin complexes. Thus, MAO-B enzyme is reversibly inactivated via this new interesting inhibitor ([Fig. 2](#f0010){ref-type="fig"}). Considering the previously reported pharmacokinetic properties of sesamin, which reveal its efficient absorption and wide distribution mainly in liver and kidney as a metabolic form, sesamin may serve as a safer alternative to the classical irreversible inhibitors ([@b0135]).Fig. 2Analysis of the nature of binding of sesamin with recombinant human MAO-B by recovery of the catalytic activity of the enzyme after dialysis dissociation. \[Each bar shows mean ± SD of triplicate values\].

3.5. Antimicrobial and antiprotozoal activities {#s0080}
-----------------------------------------------

Compound **5** showed good trypanocidal activity against *Trypanosoma brucei* with IC~50~ and IC~90~ values of 5.75 and 6.78 µg/mL, respectively compared to the positive control, DFMO with IC~50~ and IC~90~ values of 3.59 and 8.09 μg/mL, respectively. Compound **7** showed good antibacterial activity against *M. intercellare* with an IC~50~ of 10.96 µg/mL compared to the positive control ciprofloxacin (IC~50~ value of 0.399 µg/mL).

4. Concluding remarks and future perspective {#s0085}
============================================

Fourteen compounds were isolated from *Z. flavum* stems. Notably, compounds **5, 6, 8**--**14** were obtained from *Z. flavum* for the first time. Compound **3** (sesamin) was the most active as MAO-B selective inhibitor with an IC~50~ value of 1.45 ± 0.05 µM (K~i~ value of 0.473 ± 0.076 μM) through a mixed enzyme blockade mechanism. The reversible inactivation of MAO-B via sesamin was experimentally confirmed. A properly designed in vivo studies and clinical application of sesamin should be conducted. Additionally, structure-activity relationship studies that comparing sesamin with its analogues and derivatives worth careful examination to determine the essential functional groups conferring the desired activity of sesamin, unlock the therapeutic potentiality of these structurally-related candidates and may illuminate more active drugs that possess improved pharmaceutical characteristics.
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[^1]: The IC~50~ values computed from the dose response inhibition curves are mean ± SD of triplicate observations.na, not active at 100[μM]{.ul}.

[^2]: Values are mean ± SD of triplicate experiments.
